Skip to content | Change text size
 

CVH Enabling Facilities and Enabling Groups

  • The Proteomics Facility operates as Australia’s hub within the world-wide Human Proteome Organisation. It is equipped with e.g. high throughput 1 & 2 D gels, N-terminal peptide sequencing (AB Procise), MALDI ToF, ToF MS and MS/MS (AB 4700), Analytical LC’s (Facility Head: Prof Ian Smith).
  • The Blood Cell Biology Group (Head: Prof Michael Berndt)
  • The Free Radical Core Facility (FRCF) works towards the visualisation of diseased heart and vessels. The FRCF will have access to e.g. fluorescence, luminescence, gas and liquid chromatography/mass spectrometers, Electron Spin Resonance (ESR) and ESR imaging devices as well as low frequency Overhauser-enhanced MRI (Facility Head: Dr Stavros Selemidis).
  • The Vascular Biology and Pathophysiology Platform will perform preclinical in vivo/in vitro animal experimentation, vascular cell biology, biochemistry, Geno- and Phenotyping, genetically defined vascular disease models (Facility Head: Dr Grant Drummond)
  • The Clinical Vascular Medicine Platform based at Southern Health to translate the research outcomes into clinical application, i.e. the group will perform clinical studies and evaluation of drug candidates, develop diagnostics and imaging techniques in vascular medicine and cardiology. The platforms’ infrastructure includes MRI, intravascular ultrasound devices, non-invasive cardiac imaging, minimally invasive and robotic cardiac surgery etc. (Head: Barry McGrath).
  • Bioengineering for modelling, data analysis, device engineering in Vascular Imaging (Head: Prof Kerry Hourigan)
  • Chemistry Division of CVH (CVHC): The role of the CVHC will be to assist in the selection and development of potential active agents in order to take the candidate (closer) to the point where it may receive external funding, i.e. resynthesis of compounds for further preliminary assays and/or the preparation of small, focussed libraries. It will also assist in the development of new contrasting and EPR imaging agents (Head: Prof Patrick Perlmutter)
  • Monash Physiology Group: (Heads: A/Prof Helena Parkington and Dr Kate Denton)
  • The Small Animal Imaging Facility is part of the Monash Biomedical Imaging Initiative adjacent to the Australian Synchrotron, which also includes Large Animal Imaging and early Human Imaging facilities (Head Prof. David Reutens). Prof Harald Schmidt and Prof David Copolov coordinate the program.
  • RMIT University for in vitro Diagnostic Assay Development and Registration (external partner, Head Prof Harry Majewski)
  • RDDT Pty at RMIT for Preclinical Drug Evaluation and Registration (strategic partner)
  • The Bernhard O’Brian Institute for preclinical drug evaluation on angiogenesis and tissue engineering (external partner, Head: Prof Greg Dusting)